Eupraxia (EPRX) news
Recent news
Eupraxia Pharmaceuticals Q2 net income USD -14.5 million
Eupraxia Pharmaceuticals Inc. (TSX: EPRX) reported a net loss of USD -14.5 million for the second quarter of 2026, according to its most recent earnings release. This represents a significant increase in the net loss compared to the same period in 2025, when the company recorded a net loss of $8.7…
AInvest Wire · Aug 11, 2026Eupraxia Pharmaceuticals Inc files for mixed shelf of up to $300 mln - SEC filing
AInvest Wire · Aug 6, 2026Eupraxia Pharmaceuticals strengthens executive leadership team to support next phase of growth
AInvest Wire · Jul 13, 2026Eupraxia Pharmaceuticals strengthens board with three industry leaders in drug development and commercialization
AInvest Wire · Jul 7, 2026Eupraxia Pharmaceuticals Inc: Oppenheimer initiates coverage with outperform rating; price target $17
Oppenheimer has initiated coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with an Outperform rating and a price target of $17.00 , according to a report released on June 26, 2026. This represents a significant upside from the current trading price of $6.41. The firm highlighted the potential of…
AInvest Wire · Jun 26, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.